Stockscreener 앱 받기
2.00
2.04%
0.04
시간 외 거래:
1.99
-0.01
-0.50%
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Price action breakdown for Opus Genetics Inc.July 2025 Trade Ideas & Smart Swing Trading Techniques - newser.com
Real time breakdown of Opus Genetics Inc. stock performanceJuly 2025 Highlights & Reliable Breakout Forecasts - newser.com
Is Opus Genetics Inc. (R3X1) stock at risk of policy regulationInsider Selling & Stepwise Trade Execution Plans - newser.com
Opus Genetics Inc. stock momentum explained2025 Winners & Losers & Safe Entry Momentum Tips - newser.com
Applying chart zones and confluence areas to Opus Genetics Inc.2025 Retail Activity & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Opus Genetics Inc. stock a safe haven assetWeekly Stock Recap & Consistent Growth Equity Picks - newser.com
Can Opus Genetics Inc. stock maintain operating marginsJuly 2025 Sentiment & Stepwise Trade Execution Plans - newser.com
Does Opus Genetics Inc. stock trade at a discount to peers2025 Historical Comparison & Real-Time Stock Entry Alerts - newser.com
Can Opus Genetics Inc. stock hit analyst price targetsQuarterly Earnings Summary & Fast Exit and Entry Strategy Plans - newser.com
Opus Genetics (NASDAQ:IRD) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
How big funds are accumulating Opus Genetics Inc. (R3X1) stockJuly 2025 Sentiment & Low Drawdown Momentum Trade Ideas - newser.com
Can trapped investors hope for a rebound in Opus Genetics Inc.Earnings Performance Report & Risk Managed Investment Entry Signals - newser.com
What analysts say about Opus Genetics Inc R3X1 stockCapital Gains Strategies & Exceptional Profit Portfolio - earlytimes.in
Combining machine learning predictions for Opus Genetics Inc.Analyst Upgrade & Risk Adjusted Buy/Sell Alerts - newser.com
What data driven models say about Opus Genetics Inc.’s futureEarnings Overview Report & Stepwise Entry/Exit Trade Alerts - newser.com
Opus Genetics reports positive pediatric data from LCA5 gene therapy study - Eyes On Eyecare
Opus Genetics, Inc. (NASDAQ:IRD) Sees Large Increase in Short Interest - MarketBeat
How Opus Genetics Inc. (R3X1) stock performs in volatility spikesJuly 2025 Final Week & Weekly Setup with High ROI Potential - newser.com
Using R and stats models for Opus Genetics Inc. forecastingQuarterly Trade Review & High Accuracy Trade Alerts - newser.com
Opus Genetics Inc. stock daily chart insightsQuarterly Profit Review & Reliable Breakout Forecasts - newser.com
Opus Genetics (NASDAQ:IRD) Trading Up 4.4%Should You Buy? - MarketBeat
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 - GlobeNewswire
Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice - sharewise.com
Craig-Hallum Maintains Opus Genetics(IRD.US) With Buy Rating - 富途牛牛
What drives Opus Genetics Inc stock pricePrice Gap Trading Strategies & Capitalize On Fast Trends - earlytimes.in
H.C. Wainwright reiterates Buy rating on Opus Genetics stock, citing positive data - Investing.com Canada
Why pension funds invest in Opus Genetics Inc. (R3X1) stockWeekly Profit Analysis & Real-Time Sentiment Analysis - newser.com
H.C. Wainwright Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $6 - 富途牛牛
Opus Genetics Reports Positive Pediatric Data from - GlobeNewswire
Magnum Opus: Street drinks in LCA5 gene therapy phase I/II data - BioWorld MedTech
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) - GlobeNewswire
Opus Genetics Shares Encouraging Data From Inherited Retinal Degeneration Study - Nasdaq
Opus Genetics reports positive data from LCA5 gene therapy trial By Investing.com - Investing.com Australia
Opus Genetics reports positive data from LCA5 gene therapy trial - Investing.com India
Opus Genetics reports positive pediatric data from OPGx-LCA5 phase 1/2 trial in Leber congenital amaurosis type 5 (LCA5) - MarketScreener
1.11%
자본화:
|
볼륨(24시간):